Valvular & structural heart disease
Outcomes of Transcatheter Aortic Valve Replacement in Low-Risk Patients in the United States: A Report From the STS/ACC TVT Registry
Authors' conclusion
One-year outcomes among real-world trial-eligible patients are excellent, but adverse events are higher compared with published clinical trial data, likely because of greater comorbidity burden and lower baseline Kansas City Cardiomyopathy Questionnaire score.
Study context
- Population
- Heart team-designated low-risk patients undergoing transcatheter aortic valve replacement (TAVR) for trileaflet severe, symptomatic AS, US, January 2020 to March 2024trial-eligible a subset of low-risk
- Participants
- 68,194 vs 42,093
- Exposure
- Heart team-designated low-risk vs low-risk trial-eligible subset
- Heart team-designated low-riskn = 68,194
- Trial-eligiblen = 42,093
- Outcome
- Mortality, stroke, new pacemaker, and "alive and well" (alive with KCCQ score ≥60 and ≤10-point decrease from baseline)
- Follow-up
- 30 days and 1 year
Methodological detailsSTS/ACC TVT Registry, multivariable models
- STS/ACC TVT Registry
- Multivariable models
Main finding
As reported in the abstract
30-day outcomes · 30 days
Mortality
Stroke
New permanent pacemaker
Observational data: associations, not effects.
Further findings
1-year outcomes
Mortality
Stroke
Alive and well
Predictors of 1-year mortality
- Notable multivariable predictors: AF, nontransfemoral access, lower baseline KCCQ score
Original publication
Outcomes of Transcatheter Aortic Valve Replacement in Low-Risk Patients in the United States: A Report From the STS/ACC TVT Registry. Circulation. Published 3 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →